Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

UFS sets deadline for applications
2004-11-11

The University of the Free State (UFS) calls on all prospective students wishing to study at the UFS in 2005 to submit their applications for admission by no later than 30 November 2004.

“This applies to first-year students, senior students who have interrupted their studies for at least one year and undergraduate students from other educational institutions,” said Mr Vernon Collett, Registrar: Academic Student Services at the UFS.

According to Mr Collett, all applications for admission that are received after 30 November 2004 and up to no later than 15 January 2005, will be regarded as pending.

“Since student numbers are now limited by government policy and depending on availability in educational programmes, these applications will be subject to consideration by the relevant dean,” said Mr Collett.

Prospective students who want to apply must pay a non-refundable fee of R100 into a designated account, which will be provided when the application form is sent to them. The signed application form must be accompanied by a certified copy of the prospective student’s identity document or passport and a proof of payment of the application fee. The application form of a minor must be signed by his/her parent or guardian and the field of study should be clearly indicated.

“A total of 21 049 students are registered at the UFS main campus this year. We expect a considerable number of applications and foresee that our numbers for next year will be similar to what it is now,” said Mr Collett.

First-time entering first-year students will be welcomed by the Rector and Vice-Chancellor of the UFS, Prof Frederick Fourie, on 15 January 2005 at 11:00 in the Callie Human Centre on campus.

Prospective students who want to apply or who have any enquiries can call (051) 401-3000 or visit the UFS web site at www.uovs.ac.za.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
11 November 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept